A fixed dose combination of telmisartan, and a thiazide diuretic in the treatment of hypertension
Authors:
Prof. MUDr. Jiří Vítovec, CSc.; Fesc 1; MUDr. Jiří Slíva, Ph.D. 2
Authors‘ workplace:
Mezinárodní centrum klinického výzkumu –
I. interní kardio-angiologická klinika LF MU
a FN u sv. Anny v Brně
1; Ústav farmakologie 3. LF UK, Praha
jiri. vitovec@fnusa. cz
2
Published in:
Kardiol Rev Int Med 2013, 15(2): 107-110
Category:
Overview
The article gives an overview of the risk factors for hypertension and the appropriate indication for using a fixed combination of telmisartan and hydrochlorothiazide. It cites large, multi‑centre clinical trials that demonstrate the efficacy and safety of telmisartan in patients with hypertension and also a meta‑analysis of treatment with either telmisartan alone (TELMI) or in combination with hydrochlorothiazide (HCTZ) which shows that it is a very well tolerated and safe treatment for patients across a wide age range.
Keywords:
hypertension – fixed dose combination – telmisartan – hydrochlorothiazide
Sources
1. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta‑analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290– 300.
2. Corrao G, Nicotra F, Parodi A et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011; 58: 566– 572.
3. Dickson M, Plauschinat CA. Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed‑dose vs free‑ combination treatment. Ethn Dis 2008; 18: 204– 209.
4. Weber MA, Jamerson K, Bakris GL et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013; 381: 537– 545.
5. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547– 1559.
6. Verdecchia P, Gentile G, Angeli F et al. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin‑angiotensin system blockers. Ther Adv Cardiovasc Dis 2012; 6: 81– 91.
7. Tobe SW, Clase CM, Gao P et al. ONTARGET and TRANSCEND Investigators. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123: 1098– 1107.
8. Ries UJ, Mihm G, Narr B et al. 6- Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure‑activity relationships. J Med Chem 1993; 36: 4040– 4051.
9. Kakuta H, Sudoh K, Sasamata M et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25: 41– 46.
10. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma‑ modulating activity. Hypertension 2004; 43: 993– 1002.
11. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637– 645.
12. Parati G, Bilo G, Redon J. The effects of telmisartan alone or with hydrochlorothiazide on morning and 24- h ambulatory BP control: results from a practice‑based study (SURGE 2). Hypertens Res 2013; 36: 322– 327.
13. Lacourcière Y, Gil‑ Extremera B, Muller O et al. Efficacy and tolerability of fixed‑dose combinations of telmisartan plus HCTZ with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57: 273– 279.
14. Takagi H, Mizuno Y, Goto SN et al. Overview of telmisartan for blood pressure reduction among angiotensin II receptor blockers: A meta‑analysis of head‑ to‑ head randomized trials. Int J Cardiol 2012; http:/ / dx.doi.org/ 10.1016/ j.ijcard.2012.11.086.
15. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: A retrospective analysis of 50 studies. Blood Press Suppl 2008; 1: 32– 40.
16. Lacourcière Y, Tytus R, O‘Keefe D et al. Efficacy and tolerability of a fixed‑dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens 2001; 15: 763– 770.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2013 Issue 2
Most read in this issue
- Investigations of breathing disorders related to sleep from A to Z
- Treatment of sleep related breathing disorders in patients with cardiovascular system diseases
- Recurrent acute myocardial infarction in patient with coronary artery aneurysma – a case report
- Sleep apnea and cardiovascular disease